KR20190102177A - 일부 비뇨기과적 장애의 치료에 사용하기 위한 il-8 저해제 - Google Patents

일부 비뇨기과적 장애의 치료에 사용하기 위한 il-8 저해제 Download PDF

Info

Publication number
KR20190102177A
KR20190102177A KR1020197013259A KR20197013259A KR20190102177A KR 20190102177 A KR20190102177 A KR 20190102177A KR 1020197013259 A KR1020197013259 A KR 1020197013259A KR 20197013259 A KR20197013259 A KR 20197013259A KR 20190102177 A KR20190102177 A KR 20190102177A
Authority
KR
South Korea
Prior art keywords
inhibitor
compound
pharmaceutical composition
treatment
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197013259A
Other languages
English (en)
Korean (ko)
Inventor
마르셀로 알레그리티
안드레아 아라미니
마리아 칸디다 세스타
지안루카 비앙키니
로라 브란도리니
Original Assignee
돔페 파르마써티씨 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 돔페 파르마써티씨 에스.피.에이. filed Critical 돔페 파르마써티씨 에스.피.에이.
Publication of KR20190102177A publication Critical patent/KR20190102177A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020197013259A 2017-01-03 2018-01-02 일부 비뇨기과적 장애의 치료에 사용하기 위한 il-8 저해제 Ceased KR20190102177A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17150176.0 2017-01-03
EP17150176.0A EP3342407A1 (en) 2017-01-03 2017-01-03 Il-8 inihibitors for use in the treatment of some urological disorders
PCT/EP2018/050009 WO2018127469A1 (en) 2017-01-03 2018-01-02 Il-8 inihibitors for use in the treatment of some urological disorders

Publications (1)

Publication Number Publication Date
KR20190102177A true KR20190102177A (ko) 2019-09-03

Family

ID=57758480

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197013259A Ceased KR20190102177A (ko) 2017-01-03 2018-01-02 일부 비뇨기과적 장애의 치료에 사용하기 위한 il-8 저해제

Country Status (14)

Country Link
US (1) US20190336484A1 (https=)
EP (2) EP3342407A1 (https=)
JP (1) JP2020503267A (https=)
KR (1) KR20190102177A (https=)
CN (1) CN109937037A (https=)
AU (1) AU2018206134A1 (https=)
BR (1) BR112019009588A2 (https=)
CA (1) CA3046531A1 (https=)
EA (1) EA201991357A1 (https=)
IL (1) IL267577A (https=)
MA (1) MA47199A (https=)
MX (1) MX2019007972A (https=)
WO (1) WO2018127469A1 (https=)
ZA (1) ZA201902427B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3868368A1 (en) * 2020-02-21 2021-08-25 Dompe' Farmaceutici S.P.A. Cxcl8 (interleukin-8) activity inhibitor and corticosteroid combination and pharmaceutical composition and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1212051A4 (en) * 1999-08-27 2004-03-31 Merck & Co Inc METHOD FOR TREATING OR PREVENTING CHEMICAL PROSTATITIS OR CHRONIC POOL PAIN
PL1776336T3 (pl) 2004-03-23 2010-06-30 Dompe Farm Spa Pochodne kwasu 2-fenylopropionowego i zawierające je kompozycje farmaceutyczne
EP2166006A1 (en) 2008-09-18 2010-03-24 Dompe' S.P.A. 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
WO2010078403A2 (en) 2008-12-30 2010-07-08 Lipella Pharmaceuticals Inc. Methods and compositions for diagnosing urological disorders
US20120076791A1 (en) * 2010-09-29 2012-03-29 Philip Bosch Methods Of Treating Chronic Prostatitis/Chronic Pelvic Pain Syndrome
CN105582134A (zh) * 2014-09-12 2016-05-18 青岛华之草医药科技有限公司 一种治疗前列腺炎的中药组合物
EP3117835A1 (en) * 2015-07-14 2017-01-18 Dompé farmaceutici s.p.a. Il-8 inhibitors for use in the treatment of certain urological disorders

Also Published As

Publication number Publication date
WO2018127469A1 (en) 2018-07-12
IL267577A (en) 2019-08-29
MX2019007972A (es) 2019-09-09
EP3342407A1 (en) 2018-07-04
MA47199A (fr) 2019-11-13
JP2020503267A (ja) 2020-01-30
BR112019009588A2 (pt) 2019-08-06
EA201991357A1 (ru) 2019-12-30
CA3046531A1 (en) 2018-07-12
AU2018206134A1 (en) 2019-05-23
CN109937037A (zh) 2019-06-25
EP3565545A1 (en) 2019-11-13
US20190336484A1 (en) 2019-11-07
ZA201902427B (en) 2020-08-26

Similar Documents

Publication Publication Date Title
Lee et al. Resolvin D3 controls mouse and human TRPV1-positive neurons and preclinical progression of psoriasis
TWI532480B (zh) 以斑馬魚模組進行藥物篩選之方法及篩選所得藥物
US20250032461A1 (en) Il-8 inihibitors for use in the treatment of some urological disorders
WO2016118632A1 (en) Prevention and treatment of itch with an mrgpr antagonist
Shi et al. Angiotensin II as a morphogenic cytokine stimulating fibrogenesis of human tenon's capsule fibroblasts
JP2004531514A (ja) 尿失禁の処置のための選択的ｃｏｘ−２阻害剤の使用
US20210017268A1 (en) Methods for treating alcoholic liver disease, alcohol-induced brain injury and reducing alcohol addiction
Girolami et al. Differential expression and potential role of SOCS1 and SOCS3 in Wallerian degeneration in injured peripheral nerve
CN113194946B (zh) 用于治疗血管性埃勒斯-当洛斯综合征和有关障碍的组合物和方法
Jin et al. A small-molecule JNK inhibitor JM-2 attenuates high-fat diet-induced non-alcoholic fatty liver disease in mice
Qu et al. Neutrophil extracellular traps facilitate sympathetic hyperactivity by polarizing microglia toward M1 phenotype after traumatic brain injury
Sun et al. Screening of potent RIPK3 inhibitors to attenuate necroptosis and inflammation in mouse traumatic brain injury models
KR102174191B1 (ko) 조직 재생 및 저하된 조직 기능의 회복을 자극하기 위한 제제로서의 디카르복시산의 비스아미드 유도체
KR20150138225A (ko) 항당뇨병성 및 다른 유용한 활성을 갖는 식물 추출물
KR20190102177A (ko) 일부 비뇨기과적 장애의 치료에 사용하기 위한 il-8 저해제
JP2024540439A (ja) 叢状神経線維腫の治療又は予防に使用するためのニトロキソリン
Wei et al. Albiflorin attenuates sepsis-induced acute lung injury (ALI) via the TLR-4/NF-κB pathway
US20160287667A1 (en) Methods and compositions for rejuvenating neuromuscular junctions
Su et al. PCSK9 exacerbates sevoflurane-induced neuroinflammatory response and apoptosis by up-regulating cGAS-STING signal
KR20250047828A (ko) 특발성 폐 섬유증의 약물 표적
US20190201490A1 (en) Methods and compositions for the treatment of secretory disorders
Xing et al. Blockade of KCa3. 1 ameliorates rheumatoid arthritis by suppressing macrophage M1 polarization via the NLRP3 inflammasome signaling pathway
Yuan et al. Rosuvastatin Attenuates Blood–Brain Barrier Dysfunction after ICH Through Modulation of CXCL12-Associated VEGFR2/p38 MAPK Signaling
Fan Impaired Renal Hemodynamics and Glomerular Hyperfiltration Contribute to Hypertension-Induced Renal Injury in γ-Adducin Knockout Rats
Hawley An Investigation of Molecular Pathways to Aid in Therapeutic Development for Neurofibromatosis Type 2

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190508

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201203

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220602

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20221004

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220602

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I